Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 393976, 4 pages
Research Article

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults

1Infectious Diseases Institute, Makerere University, P.O. Box 22418, Kampala, Uganda
2Trinity College, Dublin 2, Ireland
3Infectious Diseases Network for Treatment and Research in Africa (INTERACT), P.O. Box 7062, Kampala, Uganda
4Uganda Heart Institute, Mulago Hospital, P.O. Box 7051, Kampala, Uganda
5St. Stephen’s AIDS Trust, London SW10 9TR, UK
6University of Liverpool, Liverpool L69 3BX, UK

Received 31 August 2010; Revised 26 November 2010; Accepted 14 February 2011

Academic Editor: Kazuo Tamura

Copyright © 2011 Pauline Byakika-Kibwika et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. We aimed to assess cardiac conduction safety of coadministration of the CYP3A4 inhibitor lopinavir/ritonavir (LPV/r) and the CYP3A4 substrate artemether-lumefantrine (AL) in HIV-positive Ugandans. Methods. Open-label safety study of HIV-positive adults administered single-dose AL (80/400 mg) alone or with LPV/r (400/100 mg). Cardiac function was monitored using continuous electrocardiograph (ECG). Results. Thirty-two patients were enrolled; 16 taking LPV/r -based ART and 16 ART naïve. All took single dose AL. No serious adverse events were observed. ECG parameters in milliseconds remained within normal limits. QTc measurements did not change significantly over 72 hours although were higher in LPV/r arm at 24 (424 versus 406; 𝑃 = . 0 2 ) and 72 hours (424 versus 408; 𝑃 = . 0 0 4 ) after AL intake. Conclusion. Coadministration of single dose of AL with LPV/r was safe; however, safety of six-dose AL regimen with LPV/r should be investigated.